Health and Medicine
Jan. 20, 2022—Researchers at Vanderbilt University Medical Center have developed a new method for identifying drugs for the repurposing trials that can lead to new indications for drugs already in use.
Jan. 20, 2022—A new study found that several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the Omicron variant now sweeping across the United States.
Jan. 19, 2022—Vanderbilt researchers have discovered that early inappropriate activation of the enzyme plasmin caused by severe injury is a trigger of systemic inflammatory response syndrome and resulting organ failure.
Jan. 18, 2022—About 80% of hospital admission electronic records were missing a drug prescribed to an older adult, Vanderbilt researchers found, highlighting the need for a multipronged approach to address medication discrepancies and support safe prescribing practices.
Vanderbilt biostatisticians launch Cancer-Immu data portal for predicting response to immune checkpoint blockade immunotherapy
Jan. 14, 2022—A new data portal called Cancer-Immu established by a team of Vanderbilt University Medical Center biostatisticians can help cancer clinicians and researchers predict which patients will respond to immune checkpoint inhibitors.
Jan. 13, 2022— by Bill Snyder Researchers at Case Western Reserve University and Vanderbilt University Medical Center are pioneering the use of computer-aided image analysis to improve the prognostication and treatment of head and neck cancer. Each year in the United States, approximately 16,000 patients are diagnosed with a form of head-and-neck cancer called oropharyngeal squamous cell...
Study of fully vaccinated patients with cancer who had breakthrough COVID-19 shows 13% mortality rate
Dec. 24, 2021—New research finds that fully vaccinated patients with cancer who had breakthrough COVID-19 infections remained at high risk for hospitalization and death.
Study finds apixaban (Eliquis) is preferable to rivaroxaban (Xarelto) for stroke prevention, reduced bleeding complications
Dec. 21, 2021— by Jill Clendening There is strong evidence that the medication apixaban (Eliquis) is preferable to rivaroxaban (Xarelto) for stroke prevention in patients with atrial fibrillation (AF), with both reduced rates of severe bleeding complications as well as strokes, according to study published Dec. 21 in JAMA. An estimated 3 million to 6 million persons...